Durvalumab and Tremelimumab in Treating Patients With Muscle-Invasive, High-Risk Urothelial Cancer That Cannot Be Treated With Cisplatin-Based Therapy Before Surgery

ACTIVE NOT RECRUITING

Identifier: CI-TRIAL-00104762
Entity page: /trial/NCT02812420 ↗
Edges: 18

Neighbours: 10 cancers2 drugs
Drawn: 12 of 12 neighbours (cap 60); table lists every fetched edge

Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.

Most connectedLung Non-Small Cell Carcinoma 3,147 Malignant Colorectal Neoplasm 1,866 ABL1 298 EGFR 276 Imatinib 450 Dasatinib 321

Neighbourhood

Radial view

Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.

Edges

Every edge, grouped by relationship

Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.

Relationship	Neighbour	Direction	Evidence level	Cancer context	Support	Claim	Source	Expand
Durvalumab and Tremelimumab in Treating Patients With Muscle-Invasive, High-Risk Urothelial Cancer That Cannot Be Treated With Cisplatin-Based Therapy Before Surgery condition of …CONDITION_OFderived16 of 16show fewer
← condition of	Invasive Bladder Micropapillary Urothelial Carcinoma registry condition “Infiltrating Bladder Urothelial Carcinoma, Micropapillary Variant” mapped ALIAS	—	—	Invasive Bladder Micropapillary Urothelial Carcinoma	1	Observed	clinicaltrials	graph →
condition of

Durvalumab and Tremelimumab in Treating Patients With Muscle-Invasive, High-Risk Urothelial Cancer That Cannot Be Treated With Cisplatin-Based Therapy Before Surgery intervention of …INTERVENTION_OFderived2 of 2
← intervention of	Durvalumabmonoclonal antibody registry intervention “Durvalumab” (BIOLOGICAL) mapped ALIAS	—	—	not mapped	1	Observed	clinicaltrials	graph →
← intervention of	Tremelimumabmonoclonal antibody registry intervention “Tremelimumab” (BIOLOGICAL) mapped ALIAS	—	—	not mapped	1	Observed	clinicaltrials	graph →

Durvalumab and Tremelimumab in Treating Patients With Muscle-Invasive, High-Risk Urothelial Cancer That Cannot Be Treated With Cisplatin-Based Therapy Before Surgery intervention of …INTERVENTION_OFderived2 of 2

← intervention of

Durvalumabmonoclonal antibody

registry intervention “Durvalumab” (BIOLOGICAL) mapped ALIAS

—

not mapped

Observed

clinicaltrials

graph →